



NEONATAL MEDICATION GUIDELINE

Nystatin

Scope (Staff):	Nursing, Midwifery, Medical and Pharmacy Staff
Scope (Area):	KEMH NICU, PCH NICU, NETS WA, KEMH and OPH Postnatal Clinical Areas

This document should be read in conjunction with the [Disclaimer](#).

Quick Links

[Dose](#)

[Preparation & Administration](#)

[Side Effects & Interactions](#)

[Monitoring](#)

Restrictions

[Formulary: Unrestricted](#)

[SAS Category A](#) (cream requires approval by TGA)

Description

Antifungal

Presentation

Suspension: 100,000 units/mL

Cream: 100,000 units/g (SAS product)

Storage

Store at room temperature, below 25°C.

Dose

Prophylaxis of systemic candida

Oral:

1 mL every 8 hours.

Prophylaxis for all infants who meet the following criteria:

- All infants ≤ 32 w GA with central line(s), including UAC/UVC, long line, femoral line, Broviac
- All infants on TPN

- All infants on ventilation or CPAP
- Infants with tracheostomies until discharge from NCCU
- During antibiotic therapy and until 48 hours after completion of course

Note: Nystatin is not required for

- Term infants (unless >5d antibiotic therapy)
- Infants on postnatal wards or for infants being discharged home or back transferred before 48 hours after antibiotic course completed

Treatment of mucocutaneous candida

Oral:

1 mL every 6 hours. Continue for at least 48 hours after perioral symptoms disappear.

AND

Topical:

Apply cream topically at each nappy change. Continue treatment for 3 days after symptoms have subsided.

Dose Adjustment

Renal Impairment: Not required.

Hepatic Impairment: Not required.

Administration

Oral

Shake well before use.

Half the required dose will be applied to the oral mucosa and half given via the oro/naso gastric tube followed by 0.3mL of sterile water.

If the neonate has a coordinated suck/swallow reflex, then the oral dose may be given orally via a syringe or teat.

May be given to infants who are nil by mouth.

Topical

Dry the skin thoroughly and apply cream liberally to the affected area(s). Leave the skin exposed if feasible.

Side Effects

Common (oral): Gastrointestinal upset

Rare (topical): Rash (urticaria), irritation

Comments

Nystatin is not suitable for the treatment of invasive fungal disease.

Related Policies, Procedures & Guidelines

External Legislation, Standards and Policy (list and hyperlink)

Check if existing higher level documents to avoid content duplication- see DoH WA and National, NMHS policies, WNHS policies, ACSQHC, NSQHS, ACORN

CAHS Neonatology Clinical Practice Guidelines:

[Skin Care Guideline](#)

WNHS Clinical Practice Guidelines:

[Neonatal Care](#)

[Antimicrobial Stewardship](#)

WNHS Pharmaceutical and Medicines Management Guidelines:

[Prescribing by eligible private practicing midwives \(EPPM\) with a scheduled medicines endorsement](#)

References

Paediatric Formulary Committee. BNF for Children: 2019. Pharmaceutical Press; 2019.

Neomed Formularies. Nystatin. In: The Royal Hospital for Women [Internet]. [South Eastern Sydney, New South Wales;2021 [cited 2021 November 09]. Available from:

<https://www.seslhd.health.nsw.gov.au/royal-hospital-for-women/neomed-formularies>









Australian Medicines Handbook. Nystatin. In: Australian Medicines Handbook [Internet].

Adelaide (South Australia): Australian Medicines Handbook; 2021 [cited 2021 November].

Available from: <https://amhonline.amh.net.au/>

Blyth CC et al. Chemoprophylaxis of neonatal fungal infections in very low birth weight infants: efficacy and safety of fluconazole and nystatin. Journal of Paediatrics and Child Health 2012 Nov; 48(9):846-51.

CA Kemp, JM McDowell. Paediatric pharmacopoeia 13 (1) Melbourne; 2002

Keywords	Nystatin, Nilstat, Mycostatin, thrush, candida, candidiasis				
Document Owner:	Head of Department - Neonatology				
Author/ Reviewer	KEMH & PCH Pharmacy/Neonatology Directorate				
Version Info:	2021 (V3): New template, additional guideline links, SAS info for cream				
Date First Issued:	12/2014	Last Reviewed:	09/11/2021	Review Date:	09/11/2024
Endorsed by:	Neonatal Directorate Management Group			Date:	25/01/2022
NSQHS Standards Applicable:	<input checked="" type="checkbox"/>  Std 1: Clinical Governance <input type="checkbox"/>  Std 2: Partnering with Consumers <input type="checkbox"/>  Std 3: Preventing and Controlling Healthcare Associated Infection <input checked="" type="checkbox"/>  Std 4: Medication Safety		<input type="checkbox"/>  Std 5: Comprehensive Care <input type="checkbox"/>  Std 6: Communicating for Safety <input type="checkbox"/>  Std 7: Blood Management <input type="checkbox"/>  Std 8: Recognising and Responding to Acute Deterioration		
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.					

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2020

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.